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Understanding the mechanisms of human immunodeficiency virus type I (HIV-1) 
pathogenesis would facilitate the identification of new therapeutic targets to control the 
infection in face of current antiretroviral therapy limitations. CD74 membrane expression 
is upregulated in HIV-1-infected cells and the magnitude of its modulation correlates 
with immune hyperactivation in HIV-infected individuals. In addition, plasma level of 
the CD74 activating ligand macrophage migration inhibitory factor (MIF) is increased in 
infected subjects. However, the role played by MIF/CD74 interaction in HIV pathogenesis 
remains unexplored. Here, we studied the effect of MIF/CD74 interaction on primary 
HIV-infected monocyte-derived macrophages (MDMs) and its implications for HIV immu-
nopathogenesis. Confocal immunofluorescence analysis of CD74 and CD44 (the MIF 
signal transduction co-receptor) expression indicated that both molecules colocalized at 
the plasma membrane specifically in wild-type HIV-infected MDMs. Treatment of infected 
MDMs with MIF resulted in an MIF-dependent increase in TLR4 expression. Similarly, 
there was a dose-dependent increase in the production of IL-6, IL-8, TNFα, IL-1β, and 
sICAM compared to the no-MIF condition, specifically from infected MDMs. Importantly, 
the effect observed on IL-6, IL-8, TNFα, and IL-1β was abrogated by impeding MIF 
interaction with CD74. Moreover, the use of a neutralizing αMIF antibody or an MIF 
antagonist reverted these effects, supporting the specificity of the results. Treatment 
of unactivated CD4+ T-cells with MIF-treated HIV-infected MDM-derived culture super-
natants led to enhanced permissiveness to HIV-1 infection. This effect was lost when 
CD4+ T-cells were treated with supernatants derived from infected MDMs in which 
CD74/MIF interaction had been blocked. Moreover, the enhanced permissiveness of 
unactivated CD4+ T-cells was recapitulated by exogenous addition of IL-6, IL-8, IL-1β, 
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and TNFα, or abrogated by neutralizing its biological activity using specific antibodies. 
Results obtained with BAL and NL4-3 HIV laboratory strains were reproduced using 
transmitted/founder primary isolates. This evidence indicated that MIF/CD74 interaction 
resulted in a higher production of proinflammatory cytokines from HIV-infected MDMs. 
This caused the generation of an inflammatory microenvironment which predisposed 
unactivated CD4+ T-cells to HIV-1 infection, which might contribute to viral spreading 
and reservoir seeding. Overall, these results support a novel role of the MIF/CD74 axis in 
HIV pathogenesis that deserves further investigation.
Keywords: human immunodeficiency virus, cD74, macrophage migration inhibitory factor, primary monocyte-
derived macrophages, cD4+ T-cells, immunopathogenesis
inTrODUcTiOn
The pandemic of human immunodeficiency virus/acquired 
immuno deficiency syndrome (HIV/AIDS) is still a major public 
health concern worldwide. Combined antiretroviral therapy 
(cART) can diminish the viral load (VL) to undetectable levels, 
reducing not only morbidity and mortality but also transmis-
sion risks, with the subsequent impact on the dynamic of the 
global epidemic (1). However, cART has several limitations like 
the need of daily doses, the development of viral resistance, and 
toxicity. More importantly, the rebound of VL levels in patients 
who discontinue cART suggests the presence of long-lived viral 
reservoirs that are resistant to cART, hampering the cure of the 
infection. In addition, it is being increasingly clear that even 
effectively treated HIV-infected individuals have a greater risk 
of experiencing non-AIDS related morbidity and mortality 
events than age-matched HIV-uninfected adults, indicating 
that even effective cART cannot fully restore health. Most of 
these complications are related to immune dysfunction and 
inflammation and include gut-associated mucosal disruption, 
lymphoid tissue damage, liver dysfunction, and monocyte/
macrophage activation which ultimately lead to the develop-
ment of coagulopathies, atherosclerosis, vascular dysfunction, 
and frailty, among other effects (2). Thus, understanding the 
mechanisms underlying HIV persistence and irreversible 
immune damage is extremely important to fight the infection 
and its consequences.
CD4+ T-cells are the major targets of HIV infection followed 
by macrophages. Productive viral replication is supported 
mostly in activated CD4+ T-cells, which culminates in cell apop-
tosis. Conversely, macrophages are less permissive to HIV-1 
infection albeit more resistant to virus-mediated cell killing, 
thus viral replication proceeds for a longer time compared to 
T cells (3, 4). Both cell types play an important role since the 
onset of infection to the development of chronic inflammation 
regardless of the different viral replication strategies maintained 
in each cell type.
CD74 (also known as invariant chain or Ii) is a non-polymorphic 
type II integral membrane protein expressed by antigen-presenting 
cells. It was first described to act as a major histocompatibility class 
II-associated chaperone; but now, it is increasingly understood 
as a versatile protein with multiple roles (5–7). In the context of 
HIV-1 infection, surface CD74 expression is upregulated by Nef 
(8, 9) and Vpu (10) viral proteins. Moreover, accumulated data 
suggest that Nef-mediated CD74 upregulation might play an 
important role in HIV immunopathogenesis as: (i) this activity is 
conserved among nef alleles from HIV-1 primary isolates, HIV-2, 
and SIV (9, 11) as well as HIV-1 BF inter-subtype recombinant 
forms (12), (ii) it has been documented in in vitro infected cell 
lines [HeLa-CIITA, MelJuSo, and THP-1 (8, 13)] and also in pri-
mary CD4+ T-cells and monocyte-derived macrophages (MDMs) 
(13, 14), and (iii) modulation levels differ among progressive 
versus non-progressive infected individuals, both in adult (9) and 
pediatric populations (13). Moreover, our group has demonstrated 
that CD74 upregulation occurs on naturally infected MDMs 
obtained directly from HIV+ subjects and that the magnitude of 
this upregulation correlates with the level of immune activation 
in those subjects, providing evidence for the contribution of the 
HIV-mediated CD74 upregulation to immune damage during 
the course of infection (15).
One of the alternative activities described for CD74 is its 
ability to serve as the high-affinity binding component of the 
hete romeric receptor for macrophage migration inhibitory factor 
(MIF) (16–18). MIF is a proinflammatory cytokine that plays a 
key role in anti-stress and anti-microbial responses. It is secreted 
by different immune cells including T and B lymphocytes, 
macrophages, monocytes, and dendritic cells among others (19). 
MIF has been related to the pathogenesis of diverse inflammatory, 
infectious, autoimmune, and metabolic diseases as well as dif-
ferent types of cancer (20–33). During HIV infection, increased 
MIF plasma levels have been observed during the acute phase of 
infection and remained elevated (34, 35). On the other hand, it 
has been demonstrated that MIF was heavily produced by in vitro 
infected peripheral blood mononuclear cells (PBMCs) and also 
by uninfected gp120-stimulated PBMCs. Moreover, the addi-
tion of exogenous recombinant MIF to in vitro infected PBMCs 
increased viral replication (34).
Despite the fact that MIF is a key component of the inflam-
matory immune response, that it is elevated in plasma from 
HIV-infected subjects, and that the virus itself modulates the 
surface expression of its receptor, no reports have explored 
the role of the MIF/CD74 axis in HIV immunopathogenesis. 
Thus, the aim of this work was to study the effect of MIF/CD74 
interaction on the phenotype and the function of primary HIV-
infected MDMs, and how this axis determines the environment 
to modulate CD4+ T-cell permissiveness to infection.
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MaTerials anD MeThODs
Primary human MDM and cD4+ T-cell 
Purification and culture
Buffy coats from healthy donors were used to obtain PBMCs 
by Ficoll-Hypaque (GE Healthcare Life Sciences, USA) density 
gradient centrifugation. Monocytes were then separated from 
PBMCs by Percoll (GE Healthcare Life Sciences, USA) gradient 
technique. Isolated monocytes (purity >80% measured by flow 
cytometry) were further purified by adherence to plastic plates 
in RPMI 1640 medium (HyClone, GE Healthcare Life Sciences, 
USA). Non-adherent cells were removed after 2 h plating by means 
of extensive washes. Adherent cells were allowed to differentiate 
into MDMs in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS, Gibco, Thermo Fischer Corporation, USA), 
2 mM l-glutamine (Sigma-Aldrich, USA), 100 U/ml penicillin 
(Sigma-Aldrich USA), 100 µg/ml streptomycin (Sigma-Aldrich, 
USA), and 10  mM HEPES (Sigma-Aldrich) (from now on 
complete RPMI medium) plus 20 ng/ml recombinant granulo-
cyte monocyte-colony stimulating factor (GM-CSF, Miltenyi, 
Germany) for 4  days. After differentiation, MDM purity was 
analyzed by flow cytometry and only donors with >90% purity 
were used in subsequent assays.
CD4+ T-cells were isolated from buffy coats by negative 
selection using the RosetteSep kit (Stem cell, Canada). Purified 
cells (>95% purity by flow cytometry) were cultured in complete 
RPMI medium plus 25  ng/ml IL-2 (BioLegend, USA). Culture 
plates were incubated at 37°C in a humidified atmosphere with 
5% CO2.
Virus Production and infections
GFP-expressing X4-tropic HIV-1 virus stock was produced 
by transfecting 293 T  cells using the X-tremeGENE 9 DNA 
transfection reagent (Roche, Switzerland) with the pBR43IeG-
nef+plasmid (kindly provided by Dr. Michael Schindler). This 
plasmid encodes the full-length HIV genome plus the reporter 
protein GFP (pBR-NL4-3 nef-IRES-eGFP, NefWT virus). 
Similarly, a Nef-defective virus (ΔNef) was produced using 
the pBR43IeG-nefSTOP plasmid. When stated, a pseudotyped 
X4-tropic virus, generated by adding a plasmid encoding the 
vesicular stomatitis virus (VSV) protein G to the transfection 
solution, was used. Also, an R5-tropic HIV-1 viral stock was 
produced by infecting primary MDMs from healthy donors 
with the HIV-1 BAL strain. Finally, an R5- and a dual (R5X4)-
tropic transmitted/founder (T/F) infectious molecular clones 
(IMCs) were selected from the full panel of T/F IMCs avail-
able at the NIH AIDS Reagent program [Division of AIDS, 
NIAID, NIH: Cat #11746 and 11744, respectively, from Dr. 
John Kappes (36–39)]. Both T/F viral stocks were produced 
by transfecting 293 T  cells using the X-tremeGENE 9 DNA 
transfection reagent. Culture supernatants were harvested 48 h 
post-transfection (for the NL4-3 and T/F viruses) or 14 days 
post-infection (for the BAL R5-tropic stock). In all cases, cul-
ture supernatants were clarified by centrifugation at 600 g for 
15 min at 4°C, fractioned and stored at −80°C until use. Viral 
titer was estimated by p24 antigen quantitation by ELISA (Sino 
Biological Inc., China).
Monocyte-derived macrophages were infected with the 
R5-tropic viruses (either with the BAL or the R5-tropic T/F 
strain) using a ratio of 1 ng p24/106 cells. MDMs to be evalu-
ated by immunofluorescence microscopy were infected with the 
VSV-G pseudotyped X4-virus and CD4+ T-cells were infected 
using the X4-tropic virus (either the NL4-3 or the dual-tropic 
T/F strain) by spinoculation (1,200 g for 1.5 h at 37°C) using a 
ratio of 150 ng p24/106 cells in both cases. After adsorption, the 
inoculum was removed and cells were washed twice in RPMI 
medium.
human samples
Plasma from 13 HIV seronegative healthy donors (HIV−) and 13 
individuals with recent HIV-1 infection (HIV+) were obtained. 
Samples from HD were obtained from eligible voluntary blood 
donors >18 years old who completed a survey on blood donation 
which particularly excludes persons who had been exposed to 
HIV; and were screened for serological markers before being 
accepted as donors. HIV-infected subjects were enrolled as part 
of an ongoing acute/early primary HIV infection cohort from 
Argentina (40–45). This study was reviewed and approved by 
two institutional review boards: Comité de Ética Humana, 
Facultad de Medicina, Universidad de Buenos Aires and Comité 
de Bioética, Fundación Huésped (Buenos Aires, Argentina). Both 
HIV-infected participants and HD provided written informed 
consents accepting to participate in this study in accordance with 
the Declaration of Helsinki.
immunofluorescence Microscopy
Monocyte-derived macrophages obtained as mentioned above 
were cultured over coverslips and infected either with the pseu-
dotyped GFP-expressing Nef wild type (WT) virus or the pseu-
dotyped GFP-expressing Nef-defective (ΔNef) virus. Uninfected 
cells were used as controls. Three days post-infection, MDMs 
were fixed and permeabilized with Cytofix-Cytoperm buffer 
(BD Biosciences) following the manufacturer’s instructions and 
blocked with Cytoperm wash buffer plus 2% FBS. MDMs were 
subsequently stained overnight with an anti-CD44 antibody 
(BioLegend). The following day, cells were washed three times 
and stained with an Alexa546-conjugated anti-mouse antibody 
(Jackson, MS, USA) during 1 h. Finally, cells were washed three 
times, treated again with cytofix-cytoperm buffer, blocked, 
and stained overnight with an APC-conjugated anti-CD74 
antibody (BioLegend, USA). After three final washes, cells 
were fixed and mounted with DAPI-Fluoromount-G (Thermo 
Fisher Scientific) and analyzed in an Olympus FV-1000 
(Olympus, Tokyo, Japan) microscope with a Plapon 60×/1.42 
NA oil immersion objective and using FV10-ASW v.01.07.03.00 
software. Cross-sectional quantitation of mean fluorescence 
intensity (mFI) was performed using Image J software. Single 
stained controls were performed in order to exclude channel 
spillover (cells stained only with APC-conjugated anti-CD74 
antibody or the anti-CD44 antibody followed by Alexa546-
conjugated anti-mouse antibody staining). Also, individual 
isotype controls were performed in order to exclude unspecific 
antibody binding and cross-reactivity with the secondary 
antibody.
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evaluation of cD74 Modulation
After infection with the WT or ΔNef GFP-expressing viruses, 
MDMs were detached with trypsin (Gibco) and stained with 
an anti-CD74-PE (Santa Cruz Biotechnology, USA). Cells were 
washed and analyzed in a BD FACSCanto flow cytometer (BD 
Biosciences) using the FACSDiva v8.0.1 software (BD Biosciences) 
or FlowJO v10 (Data Analysis Software, LLC). HIV-mediated 
CD74 upregulation was calculated as the ratio between the FL2 
median fluorescence intensity (MFI) of infected (GFP+) versus 
uninfected (GFP−) cells.
recombinant cytokines and antibodies
Recombinant human MIF (rhMIF) was prepared as described 
elsewhere (46) (endotoxin content < 0.1 EU/ml). MIF antagonist 
MIF098 [3-(3-hydroxybenzyl)-5-methylbenzooxazol-2-one] was 
dissolved in DMSO at a concentration of 149  µM (47). The 
neutralizing anti-MIF monoclonal antibody (clone NIHlllD.9) 
was obtained from ascites after purification using protein A/G 
spin column and resuspended at 5.15 mg/ml (48, 49). A CD74 
blocking antibody (BD Pharmingen, clone LN2), the recombi-
nant human cytokines IL-6, IL-8, IL-1β (BioLegend), and TNFα 
(MiltenyiBiotec), and the cytokine neutralizing antibodies 
anti-IL-8 (R&D Systems), anti-IL-6, anti-IL-1β, and anti-TNFα 
(BioLegend) were obtained.
MDM stimuli
Monocyte-derived macrophages were infected with the R5-tropic 
HIV and the infection was left to progress. At day 11, infec-
tion percentage was evaluated by p24 intracellular staining 
as described in the following paragraph (Figure S1 in Sup-
plementary Material). After that, MDMs were washed twice with 
PBS 1× (Sigma) and rhMIF was added to a final concentration 
of 1, 10, or 25 ng/ml. Cells were incubated at 37°C for 8 h until 
the supernatant was collected. When denoted, pretreatment 
with the αCD74 blocking antibody (or the appropriate isotype 
control) was performed at 5 ng/ml for 30 min. In some experi-
ments (TLR4 expression), Fc receptors were blocked for 10 min 
before the addition of the αCD74 blocking antibody (or its 
isotype-matched control) with an Fc blocking reagent from BD 
Biosciences.
evaluation of Tlr4 expression
After MIF stimulation, infected and uninfected MDMs were 
harvested and stained with a PE-conjugated anti-TLR4 antibody 
(BioLegend) for 30 min at 4°C. Following incubation, cells were 
washed, fixed, and permeabilized using the Cytofix/Cytoperm 
kit (BD Biosciences) following the instructions provided by 
the manufacturer. Then, intracellular p24 antigen was stained 
using an anti-p24-FITC antibody (KC57-FITC, Coulter-clone, 
Beckman Coulter, USA) for 30  min at 4°C. Cells were then 
washed, fixed, and acquired in a BD FACSCanto flow cytometer. 
Data acquisition was performed using the BD FACSDiva software 
and analyzed subsequently with FlowJO v10 software (Data 
Analysis Software, LLC). An isotype-matched FITC-conjugated 
non-specific antibody was used to set the p24-negative popula-
tion accurately.
First, single cells were gated in a forward scatter (FSC)-height 
(FSC-H) versus an FSC-area (FSC-A) plot. Then, gating was 
performed on living MDMs in an FSC versus a side scatter 
(SSC) plot. Infected cells were identified in an SSC versus FL-1 
(FITC) plot as p24 positive events (Figure S1 in Supplementary 
Material). Bystander cells were identified as the p24-negative 
population on the same plot. TLR4 median fluorescence intensity 
(MFI) was determined for uninfected, infected, and bystander 
cells. Modulation of TLR4 expression was calculated as the ratio 
between MFI corresponding to infected or bystander versus 
uninfected cells.
cytokine Quantitation
The levels of the following cytokines were evaluated in MDM 
supernatants using commercially available ELISA sets: IL-8, 
IL-6, IL-1β, TNFα, IL-10 (ELISA MAX Deluxe kits, BioLegend) 
and sICAM (DouSet ELISA, R&D Systems). MIF plasma levels 
were evaluated using an in-house ELISA constructed with an 
anti-human MIF antibody pair and an MIF standard obtained 
from BioLegend.
Permissiveness induction in Unactivated 
cD4+ T-cells
Unactivated CD4+ T-cells were incubated with supernatants 
(1/2,000 dilution) from MIF-treated or untreated MDMs, for 
72 h at 37°C. Before incubation, supernatants were clarified for 
15 min at 600 g and UV-inactivated for 30 min (253.7 nm, 15 cm 
away from the light source). After that, cells were washed and 
infected with an X4-tropic HIV. Supernatants were collected 
daily for p24 antigen quantitation till day 7 post-infection. 
Phytohemagglutinin- (PHA, 2.5  ng/ml, Sigma-Aldrich, USA) 
and RPMI-treated CD4+ T-cells were used as positive and nega-
tive controls, respectively.
Alternatively, unactivated CD4+ T-cells were stimulated with 
recombinant IL-1β, IL-6, IL-8, and TNF-α, either alone or in 
combination, for 72 h prior to infection.
cD4+ T-cell Phenotype, Viability,  
and infection Percentage
The expression of CD38, CD69, HLA-DR, CD25, PD-1, and 
CD28 surface molecules were analyzed by flow cytometry after 
CD4+ T-cell stimulation with MDMs-derived supernatants for 
72  h. Percentages of cells expressing the markers mentioned 
above as well as their MFI were recorded. Initial gating was 
performed on lymphocytes followed by gating on CD4+ events. 
Isotype-matched non-specific antibodies were used in each 
sample to set the corresponding negative populations accurately.
In addition, CD4+ T-cells were harvested from day 1 to 7 
post-infection and both cell viability and infection percentages 
were evaluated by flow cytometry. First, single cells were gated 
in an FSC-H versus an FSH-A plot. Then, living lymphocytes 
were gated an FSC versus an SSC plot (%viability). Subsequently, 
infected cells were identified in an FSC-H versus GFP plot (Figure 
S1 in Supplementary Material). Data acquisition was performed 
in a BD FACSCanto flow cytometer using the BD FACSDiva 
software and analyzed subsequently with FlowJO v10 software 
(Data Analysis Software, LLC).
FigUre 1 | CD74 upregulation in human immunodeficiency virus (HIV)-infected monocyte-derived macrophages (MDMs) and macrophage migration inhibitory 
factor (MIF) plasma levels in HIV+ subjects. (a) Flow cytometry analysis of CD74 surface expression in primary uninfected MDMs (left panel); infected MDMs with a 
Nef-defective virus expressing the reporter molecule GFP (ΔNef HIV-1, middle panel); and infected with a wild type (WT) HIV-1 also expressing the reporter molecule 
GFP (WT HIV, right panel). The plots show CD74 versus GFP expression (HIV-1 infection) on MDMs [gated previously in a forward scatter (FSC) versus side scatter 
plot]. In each dot plot, two different populations were gated: the HIV-1 negative population (GFP negative) and the HIV-1 positive population (GFP positive). One 
representative healthy donor, out of three donors, is shown. (B) Quantitation of Nef-mediated upregulation of CD74, calculated as the ratio between FL-2 MFI 
obtained for cells infected with the WT virus and the FL-2 MFI obtained for cells infected with the ΔNef virus. Each black dot represents one out of three 
independent experiments (donors). Horizontal red bars stand for the mean value. (c) MIF concentration in plasma obtained from HIV-negative (HIV−, N = 13) and 
HIV-positive (HIV+, N = 13) donors. Each plasma was evaluated in duplicate. Dots represent the average of duplicates for each donor. Data were normally 
distributed and analyzed by two-tailed unpaired Student’s t-test. Horizontal lines within boxes represent the median and whiskers extend from min to max. 
****p < 0.0001.
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Data analysis
Experiments were performed at least three independent times 
and analyzed using parametric tests, unless otherwise stated (see 
exact number of independent experiments in each figure legend). 
Data normality was assessed using the Shapiro–Wilk test. All tests 
were considered significant when p < 0.05 (GraphPad Prism 7 
Software).
resUlTs
cD74 is Upregulated in In Vitro hiV-
infected MDMs and This effect is 
accompanied by higher MiF Plasma 
levels in hiV-infected subjects, 
compared to hiV-negative Donors
Nef-mediated CD74 upregulation is a well-described phenom-
enon. More specifically, this was shown to occur in in  vitro 
HIV-infected primary MDMs (13) and in an ex vivo model of 
MDMs obtained from HIV-infected subjects (15). Figure  1A 
depicts surface CD74 expression in one representative MDM 
donor. CD74 expression was monitored in uninfected cells 
(UN, left panel) as well as in cells infected with a Nef-defective 
virus (ΔNef, middle panel) or a Nef-expressing virus (WT, right 
panel). In the cultures infected with the WT virus, CD74 MFI 
was significantly higher in GFP-expressing cells (i.e., infected) 
when compared to GFP-negative cells (i.e., uninfected). On the 
contrary, no differences were observed in cultures infected with 
the Nef-defective virus when comparing infected versus unin-
fected cells. Figure  1B compiles the upregulation magnitude 
from three different donors (relative to the Nef-defective virus). 
On the other hand, it has been reported that the plasma levels 
of the CD74 ligand MIF were elevated during HIV infection 
(34, 35). To confirm this, MIF concentration was evaluated in 
plasma from recently HIV-infected subjects enrolled as part of 
the Grupo Argentino de Seroconversión study group. In line with 
the previous reports, our results indicated that the MIF plasma 
level during the acute HIV infection (<6-month post-infection) 
was 30-fold higher when compared to uninfected individuals 
(Figure 1C).
Plasma Membrane expression of cD74 
and cD44, the signaling component of the 
MiF receptor complex, are increased in 
WT hiV-infected MDMs
We hypothesized that the increased CD74 expression found 
in HIV-1 infected MDMs may translate into enhanced MIF 
FigUre 2 | CD74 and CD44 expression in uninfected and infected monocyte-derived macrophages (MDMs). (a) Confocal immunofluorescence microscopy of 
primary uninfected MDMs (UN, upper panels); primary ΔNef human immunodeficiency virus (HIV)-infected MDMs (ΔNef, middle panels); and primary wild type (WT) 
HIV-infected MDMs (WT, lower panels). From left to right: bright field, GFP (HIV-1 infection), CD74 staining and CD44 staining are shown, in one representative cell 
for each condition. (B) Plots show cross-sectional mean fluorescence intensity (mFI) for CD74 (left axis, cyan line) and CD44 (right axis, red line) corresponding to 
the depicted cells (in the lower panel, cross-sectional mFI was evaluated in the cell pointed with an arrow). The black lines indicate the area comprising the cell 
according to the DIC. (c,D) Cross-sectional mFI quantification for CD44 (upper panel) and CD74 (lower panel) intensity at plasma membrane (c) and cytoplasm  
(D). Quantifications were performed in 15 individual cells for each condition. Bars represent mean ± SD. Data were analyzed by one-way ANOVA followed by 
Dunnett’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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receptor availability and signal transduction. Thus, the cellular 
localization of CD74 and the CD44 signaling co-receptor was 
evaluated in infected primary MDMs by confocal immunofluo-
rescence microscopy. In consonance with previous reports on 
HeLa-CIITA cells (8, 50), CD74 staining was observed mainly in 
intracellularly both in uninfected cells and in cells infected with 
the Nef-defective virus (Figure  2A). More specifically, CD74 
staining was mostly located in membranous compartments 
within the cytoplasm. This could be visualized in the images 
but it also could be inferred from cross-sectional quantitation 
of mean fluorescence intensity (mFI) by image processing 
(Figure 2B) where an uneven mFI profile characterized by dif-
ferent cytoplasmic peaks was obtained. Conversely, an intense 
CD74 signal comprising the plasma membrane was observed in 
MDMs infected with the WT virus (Figures 2A,B, lower panels). 
This is consistent with the ability of Nef to reduce the rate of 
CD74 internalization (12, 51). Surprisingly, CD44 distribution 
mirrored that of CD74 in all conditions. Particularly, both CD44 
and CD74 were strongly co-expressed at the plasma membrane 
of WT HIV-infected cells.
In order to quantitate CD44 and CD74 expression at different 
subcellular localization across all conditions, MFI cross-sectional 
quantifications corresponding to the regions encompassing only 
the plasma membrane (Figure 2C) or the cytoplasm (Figure 2D), 
both for CD74 and CD44, were performed in all infection con-
ditions. Results again indicated that there is a substantial overlap 
between both molecules in all conditions but that the staining 
pattern was significantly different in WT-infected cells compared 
both to uninfected and ΔNef-infected cells, being the expression 
of both molecules concentrated at the plasma membrane. These 
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data support the notion that the expression of the components 
of the main MIF receptor might be enhanced in Nef-expressing 
HIV-infected cells which in turn would be translated into higher 
responsiveness to MIF by HIV-infected cells.
MiF Modulates Tlr4 expression in hiV-
infected MDMs in a cD74-independent 
Fashion
We next investigated the well-documented action of MIF to 
upregulate TLR4 expression in MDMs. To elucidate if this 
activity was affected by HIV infection, and if it was depend-
ent of CD74 engagement, MDMs were infected with the 
R5-tropic HIV strain. Uninfected cells were used as controls. 
At day 11, cells were treated with 1, 10, or 25  ng/ml of MIF. 
These concentrations were chosen as reported previously to 
represent those observed in plasma from healthy volunteers, 
pathophysiological fluids, or plasma from HIV+ individuals, 
respectively (34, 52). In this model, cell viability at day 11 was 
83 ± 3.7% in uninfected wells and 66.8 ± 2.5% in infected wells 
post-treatment. Percentage of infection was 48.48 ± 16.8%, and 
p24 production in culture supernatant was 20.53 ± 12.7 ng/ml. 
These parameters did not differed significantly across the differ-
ent MIF concentrations evaluated here (not shown). To study 
the expression of TLR4 in uninfected (UN), bystander (By), 
and productively infected (IN) cells, the gating strategy shown 
in Figure S1 in Supplementary Material and Figure  3A was 
used. Representative results from one donor can be observed in 
Figure 3B. There, it can be observed that TLR4 expression was 
not modified by MIF treatment either in uninfected of bystander 
cells. However, TLR4 expression increased with increasing MIF 
concentration in productively infected cells. When results from 
four independent donors were expressed relative to their cor-
responding UN condition and then combined (Figure  3C) it 
could be observed that TLR4 expression peaked at 25 ng/ml MIF 
specifically in HIV-infected cells, almost doubling in magnitude 
when compared to the “no-MIF” condition. This can also be 
observed in the overlaid histograms shown in Figure 3D, where 
the MFI for the “IN plus 25 ng/ml MIF” condition is the highest. 
In order to elucidate whether an interaction between CD74 and 
MIF was responsible for a higher TLR4 expression, cells were 
pre-incubated with a neutralizing anti-CD74 antibody (or an 
isotype-matched control antibody), prior to MIF treatment at 
peak effect concentration (25 ng/ml MIF). TLR4 expression was 
significantly reduced both in the CD74-blocked condition but 
also in the control condition (Figure 3C, gray box). As MDMs 
may constitutively release MIF in low levels (53), this result may 
reflect the saturating action of autocrine/paracrine stimulation 
by endogenously released MIF or, alternatively, a non-specific 
action of Fc receptor engagement. To test the latter hypothesis, 
Fc receptors were blocked in this model (Figure  3E). When 
the FcR block was applied prior to the treatment with the anti-
CD74 blocking antibody or the isotype-matched control and 
the cells were treated with 25 ng/ml MIF, the TLR4 expression 
reverted to the levels detected in cells only treated with MIF. 
Moreover, no differences were observed between the CD74 
blocked and isotype control conditions. This indicates that the 
reduction found in TLR4 expression when cells were treated 
with the anti-CD74 blocking antibody or the isotype-matched 
control represented a non-specific response to Fc engagement. 
Collectively, these results indicate that exogenous MIF had an 
effect on TLR4 up-modulation, which was only evident in IN 
cells (not UN or By cells) but this effect could not be blocked by 
interfering MIF binding to CD74.
interaction Between cD74 and MiF 
Triggers the Production of 
Proinflammatory Mediators specifically 
From hiV-infected MDMs
Next, we aimed at investigating the requirement of CD74/MIF 
interaction in the production of proinflammatory cytokines 
from HIV-infected versus uninfected MDMs following treat-
ment with MIF. MDMs were infected with the R5-tropic HIV 
strain and uninfected cells were used as controls. At day 11 (peak 
infection), cells were treated with different MIF concentrations. 
Cell viability, infection percentages, and culture supernatant 
p24 production were as described in the previous section. 
Figures 4A,B show the raw data from one representative donor 
and the compiled data from six donors, respectively. Except 
for IL-10, most supernatants obtained from infected MDMs 
showed higher production of cytokines when treated with MIF, 
compared to the uninfected MIF-treated counterpart. While 
no-MIF effect was observed in uninfected cultures, an MIF-
dependent production of IL-8, IL-6, IL-1β, TNF-α, and sICAM 
was detected in infected cells. Compiled results (N = 6) indicated 
that the greatest effect of MIF on IL-8 production occurred at 
10 ng/ml (twofold increase). Similar observations were found for 
IL-6 (a peak fold increase of 2 and 2.5 at 10 and 25 ng/ml MIF, 
respectively), IL-1β (a peak fold increase of 8 at 25 ng/ml MIF), 
TNF-α (a peak fold increase of 26 at 1 ng/ml MIF), and sICAM 
(a peak fold increase of 2 at 1 ng/ml MIF). By contrast, no-MIF 
effect was observed in IL-10 production. These results suggest 
that MIF drive the production of proinflammatory mediators 
and that this effect is specific for HIV-infected cells. In order to 
elucidate whether an interaction between CD74 and MIF was 
responsible for the higher production of these cytokines, cells 
were pre-incubated with an anti-CD74 blocking antibody prior 
to MIF treatment at the peak effect concentrations (e.g., 25 ng/ml 
MIF for IL-8, IL-6, and IL-1β and 1  ng/ml MIF for TNF-α 
and sICAM; Figures 4A,B, gray boxes). In all cases, except for 
sICAM, CD74 blockade resulted in diminished levels of cytokine 
production similar to those observed in the no-MIF condition. 
Conversely, this effect was not observed when cells were pre-
incubated with the corresponding isotype control antibody. 
Thus, CD74/MIF interaction was a necessary condition for the 
higher production of the studied cytokines in infected cells. Of 
note, this result was not recapitulated for sICAM, suggesting an 
alternative mechanism for this mediator.
Altogether, these results reveal that MIF favors the produc-
tion of proinflammatory mediators specifically from HIV-
infected cells and demonstrate that the interaction with CD74 
is needed to achieve this effect. Moreover, they suggest a joint 
contribution of MDM infection, HIV-mediated upregulation of 
FigUre 3 | TLR4 expression after macrophage migration inhibitory factor (MIF) stimulation in primary human immunodeficiency virus (HIV)-infected monocyte-
derived macrophages (MDMs). (a) TLR4 expression in uninfected (UN, upper panel), bystander (By, lower panel), and productively infected cells identified on the 
bases of intracellular p24 staining (In, lower panel). Living MDMs were gated previously on a forward scatter versus side scatter dot plot. An isotype-matched 
FITC-conjugated antibody was used to accurately set the p24-negative population. (B) TLR4 MFI in uninfected MDMs (Un), in productively infected MDMs  
(p24 positive population within the well inoculated with the virus, In) and in the bystander uninfected MDMs (p24-negative population within the well inoculated  
with the virus, By) after MIF treatment. These data represent the results obtained from one representative donor. (c) Ratio between the TLR4 MFI of the infected  
(or bystander population) and the TLR4 MFI of the uninfected cells after treatment with MIF, with or without CD74 blockade with an anti-CD74 antibody. Fold up 
from four independent donors, evaluated in duplicate are shown collectively. Data represent the mean ± SD. (D) Flow cytometry histogram overlay for TLR4 
expression on Un, By, and In MDMs all treated with 25 ng/ml MIF (e) Ratio between the TLR4 MFI of the infected (or by-stander population) and the TLR4 MFI  
of the uninfected cells using the different CD74-blocking conditions represented in the x-axis. Data were analyzed by two-way ANOVA followed by Tukey’s  
post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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surface CD74, and MIF stimulation to promote the production 
of a proinflammatory environment.
To provide further insight into the role of MIF in these obser-
vations, infected and uninfected MDMs from three independent 
donors were treated with 25 ng/ml of MIF plus different concen-
trations of an anti-MIF neutralizing monoclonal antibody (range 
3.125–100  ng/ml, Figure  5A) or the MIF antagonist MIF098 
(range 5–100 nM, Figure 5B). Neither the anti-MIF neutralizing 
monoclonal antibody nor the MIF antagonist affected cell viabil-
ity in the concentration range tested. After incubation, produc-
tion of IL-8, IL-6, IL-1β, and IL-10 was monitored. As expected, 
a significant reduction in IL-8, IL-6, and IL-1β production was 
FigUre 4 | Continued
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FigUre 4 | Expression of cytokines after macrophage migration inhibitory factor (MIF) stimulation in primary human immunodeficiency virus (HIV)-infected and 
uninfected monocyte-derived macrophages (MDMs). (a) Expression of IL-8, IL-6, IL-1β, TNF-α, sICAM, and IL-10 in supernatants from HIV-infected (In) and 
uninfected (Un) MDMs obtained from one representative healthy donor. (B) Data combined from six independent experiments (donors), each evaluated in triplicate. 
Here, data are shown as the ratio between cytokine concentrations found under the infection condition versus the uninfected counterpart. Cells were stimulated  
with MIF as follows: 0, 1, 10, or 25 ng/ml. Data shown in the gray boxes depict CD74 blocking (10 ng/ml of αCD74 or the corresponding isotype control) followed 
by MIF stimulation (1 or 25 ng/ml as denoted). Data represent the mean ± SD. Data were analyzed by one-way ANOVA followed by Tukey’s post-test. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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observed upon MIF inhibition when using either the neutralizing 
antibody or the small molecule MIF antagonist. Serial dilution 
of both of these CD74/MIF interaction inhibitors reconstituted 
cytokine expression. Indeed, significant dose-dependent effects 
were observed, further supporting a role for MIF in promoting 
the production of proinflammatory mediators specifically from 
HIV-infected cells. No significant MIF or anti-MIF effects were 
observed on uninfected cells. Similarly, no changes were observed 
in IL-10 production.
cD74/MiF-Dependent Production of 
Proinflammatory Factors From hiV-
infected MDMs enhances Viral Production 
From Unactivated cD4+ T-cells
Then, we reasoned that conditioned media (supernatants) from 
MIF-treated HIV-infected MDMs could have an enhancing 
effect on the permissiveness of unactivated CD4+ T-cells to HIV 
infection, which are mostly naturally resistant to HIV. To test this 
hypothesis, supernatants obtained from infected and uninfected 
MDMs, treated or not with MIF, were UV inactivated and used 
to stimulate purified unactivated CD4+ T-cells. RPMI- or PHA-
treated CD4+ T-cells were used as negative and positive controls, 
respectively. At 72 h post-treatment, CD4+ T-cells were infected 
with an X4-tropic GFP-expressing viral strain, and infection 
was monitored during 7 days by flow cytometry to evaluate % of 
infected cells (GFP+, see Figure S1 in Supplementary Material) 
and by ELISA (p24 antigen) to evaluate viral production. 
Figures 6A,B depict the viral production kinetics observed in 
CD4+ T-cells treated with supernatants derived from uninfected 
and HIV-infected MDMs, respectively, treated with 0, 1, and 
25  ng/ml MIF (the 10  ng/ml condition was not evaluated). 
Viral production was very low when CD4+ T-cells were pre-
incubated with supernatants derived from uninfected MDMs 
and it was independent of MDM MIF treatment (Figure  6A). 
A similar kinetic was observed in CD4+ T-cells pre-incubated 
with supernatants from infected MDMs treated with 0 MIF 
(Figure 6B, pink line). Conversely, viral production from CD4+ 
T-cells pre-incubated with supernatants from infected MDMs 
treated with 1 ng/ml MIF (Figure 6B, red line) and 25 ng/ml MIF 
(Figure 6B, dark red line) tended to increase over time reaching 
maximal viral production at day 7 for the 1 ng/ml MIF condition 
and at day 4 for the 25 ng/ml MIF condition. This can be better 
observed in Figures  6C,D. Here, viral production from CD4+ 
T-cells pre-incubated with supernatants from infected MDMs 
treated with 1 ng/ml (Figure 6C) and 25 ng/ml (Figure 6D) is 
shown relative to the viral production from CD4+ T-cells pre-
incubated with supernatants from uninfected MDMs treated 
with the corresponding MIF concentration. Overall, results 
indicate that, at 7  days post-infection, viral production from 
initially unactivated CD4+ T-cells is significantly higher upon 
exposure to supernatants derived from infected MDMs treated 
with 1 ng/ml MIF, compared to exposure to supernatants derived 
from uninfected MDMs. Similarly, unactivated CD4+ T-cells 
sensitized with supernatants from infected MDMs treated with 
25 ng/ml MIF showed a significant, albeit transient, increase in 
viral production at day 4 post-infection, compared to the unin-
fected condition, which was later downmodulated.
Despite sustained viral production is observed from CD4+ 
T-cells treated with supernatants derived from the 25  ng/ml 
MIF-treated infected MDMs (see Figure 6B, dark red line), the 
peak effect observed at day 4 in Figure 6D is lost at later time 
points. This might be indicating that the supernatant from 
infected MDMs treated with 25 ng/ml might be enhancing cell 
permissiveness and/or favoring an earlier viral production from 
these unactivated cells.
In order to rule out the possibility of inefficient viral inacti-
vation by UV of MDM-derived supernatants, CD4+ T-cells were 
incubated with the UV-inactivated supernatants and left to 
proceed as described previously but without infecting them. At 
days 4 and 7, p24 antigen was quantified, and no viral produc-
tion was detected under either condition. This indicates that no 
viral carry-on from infected MDMs occurred. We also explored 
whether CD4+ T-cell viability and infection percentages were 
affected by the addition of supernatants derived from MDMs 
treated under the different MIF conditions. No differences in cell 
viability (Figure  6E) was observed along time for CD4+ T-cell 
treated with supernatants obtained from uninfected MDMs 
treated with the different MIF concentrations (black, dark gray, 
and light gray lines). As expected, CD4+ T-cell treated with 
supernatants obtained from infected MDMs showed a reduction 
in cell viability, compared to the uninfected condition, no dif-
ferences were observed across the different MIF concentrations 
(pink, red, and dark red lines). This indicates that cell viability 
most likely does not account for the differences observed in viral 
production. On the other hand, the infection percentage was 
higher after PHA treatment (Figure  6F). All other conditions, 
including the RPMI control, showed infection percentages <2% 
and no significant differences across treatments were observed. 
This might be indicating that the treatments with the MDM-
derived supernatant might enhance viral production from 
those few infected cells rather than promoting infection. Then, 
the effect of blocking CD74/MIF interaction in MDMs on the 
observed results was studied. For this, unactivated CD4+ T-cells 
were incubated with supernatants derived from MDMs in which 
the interaction between CD74 and MIF had been blocked with 
FigUre 5 | Effect of macrophage migration inhibitory factor (MIF) neutralization in the expression of cytokines from primary human immunodeficiency virus-infected 
and uninfected monocyte-derived macrophages (MDMs). Serial dilutions of a neutralizing αMIF antibody (clone NIHlllD.9) (a), and the MIF antagonist MIF098  
(B) were used to inhibit MIF activity in infected (In, red lines) and uninfected (Un, gray lines) MDMs at a constant concentration of this cytokine (25 ng/ml). Data 
represent three independent experiments (donors), each evaluated in duplicate. Data represent the mean ± SD. Data were analyzed by two-way ANOVA followed  
by Tukey’s post-test (intragroup analysis, In group only; ****p < 0.0001) or by Sidak’s post-test (intergroup, In versus Un; #1p < 0.05, #2p < 0.01, #3p < 0.001, 
#4p < 0.0001). Asterisks corresponding to the intragroup analysis are shown above the horizontal bars, and those from the intergroup analysis are shown above 
points corresponding to each antagonist or antibody dilution.
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FigUre 6 | Continued
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an anti-CD74 neutralizing antibody (Figure 6G). This assay was 
performed using supernatants from MDMs treated with the 
25  ng/ml condition and viral production was evaluated at day 
4 to reproduce the peak result observed in Figure 6D. Notably, 
unactivated CD4+ T-cells treated with supernatants derived from 
“CD74-blocked” MDMs were not able to recapitulate the increase 
FigUre 6 | Induction of permissiveness to human immunodeficiency virus type I (HIV-1) infection in primary CD4+ T-cells after stimulation with macrophage 
migration inhibitory factor (MIF)-treated monocyte-derived macrophages (MDMs)-derived supernatants. (a,B) Seven-day kinetics of HIV p24 antigen production  
from primary unactivated CD4+ T-cell incubated with supernatants from uninfected (a) and infected (B) MDMs treated with 0, 1, or 25 ng/ml MIF. (c,D) Ratio of  
p24 production from unactivated CD4+ T-cell incubated with supernatants from uninfected MDMs and infected MDMs treated with 1 ng/ml MIF (c) or 25 ng/ml MIF 
(D) over the no-MIF condition. (e) Percentage of living CD4+ T-cells stimulated with supernatants derived from uninfected (black, dark gray, and light gray lines)  
and infected (pink, red, and dark red lines) MDMs. (F) Percentage of infected (GFP+) CD4+ T-cells after stimulation with MDM-derived supernatants obtained  
from MIF-treated uninfected MDMs (black, dark gray, and light gray lines), infected (pink, red, and dark red lines) MDMs, RPMI (negative control, black line with 
diamonds), or PHA (positive control, black line with triangles). (g) Ratio of p24 production from unactivated CD4+ T-cell incubated with supernatants from uninfected 
MDMs and infected MDMs treated with 25 ng/ml MIF, with or without CD74 blockade with an anti-CD74 antibody. (h) Expression of surface markers on CD4+ 
T-cells subjected to 72 h stimulation with supernatants derived from infected and uninfected MDMs and exposed or not to MIF treatment (0 and 25 ng/ml MIF).  
Data represent the mean ± SD from six independent donors evaluated in duplicate. In (c,D), data were analyzed by two-way ANOVA followed by Sidak’s post-test. 
In (g), data were analyzed by two-way ANOVA followed by Tukey’s post-test. *p < 0.05, ****p < 0.0001.
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in viral production observed in the “non-blocked” condition. In 
summary, these results suggested that soluble factors released 
after MIF treatment in infected MDMs enhanced permissiveness 
of unactivated CD4+ T  cell. Moreover, the production of these 
factors appears to be dependent on CD74/MIF interaction as the 
effect was abrogated by immunoneutralization of CD74.
Finally, we investigated if preincubation with the super-
natants derived from MDMs induced CD4+ T-cell activation 
differentially as it is known that the level of cell activation 
correlates with HIV-1 infection efficiency. To assess this, the 
phenotype of CD4+ T-cells was studied after stimulation with 
MDMs-derived supernatants. The expression of CD38, CD69, 
HLA-DR, CD25, PD-1, and CD28 markers was evaluated by 
flow cytometry after 72 h. Supernatants from infected or unin-
fected MDMs treated (25 ng/ml) or not with MIF were used. No 
differences were detected in the percentage of cells expressing 
the different membrane markers (Figure  6H) or their MFI 
(not shown) among treatments. In sum, the improved viral pro-
duction observed in CD4+ T-cells after treatment with super-
natants derived from 25  ng/ml MIF-treated infected MDMs 
could not to be explained by differential cell viability, infection 
percentage, or cell activation (measured by surface markers).
In summary, we identified that the production of TNFα, 
IL-6, IL-8, and IL-1β increased significantly after CD74/MIF 
interaction in infected MDMs. Moreover, conditioned media 
from MIF-treated infected MDMs significantly enhanced viral 
production from unactivated CD4+ T-cells. Thus, the next 
step was to study a possible link between cytokines secreted 
by infected MDMs in an MIF-dependent manner and viral 
production from unactivated CD4+ T-cells. To do this analysis, 
recombinant IL-1β, IL-6, IL-8, and TNFα were used to stimulate 
primary unactivated CD4+ T-cells in the absence of any other 
stimuli at concentrations that resemble those found in MDM 
supernatants stimulated with 25 ng/ml MIF (peak effect). RPMI 
alone and PHA-supplemented RPMI were used as negative and 
positive controls, respectively. After 72 h, cells were infected, and 
viral p24 antigen was quantified. CD4+ T-cells treated with single 
cytokines or dual combinations did not alter viral production, 
regardless of the cytokines involved (data not shown). Only 
when treating CD4+ T-cells with three or four cytokines simulta-
neously viral production increased significantly compared to the 
RPMI control (Figure 7A). No differences in cell viability and 
infection percentages were observed across treatments (except 
for PHA) (Figures 7B,C). Finally, MDMs-derived supernatants 
were incubated with anti-IL-8, -IL-6, -IL-1β, and -TNFα neu-
tralizing antibodies and used as CD4+ T-cells activation stimuli. 
In line with our hypothesis, a significant reduction in viral 
production was observed under this condition, compared to the 
non-neutralized and isotype control supplemented supernatants 
(Figure 7D).
Overall, IL-1β, IL-6, IL-8, and TNFα were identified as factors 
secreted from MIF-treated HIV-infected MDMs that, in combi-
nation, exerted a transient enhancing effect on viral production 
from unactivated CD4+ T-cells.
In Vitro infections With Transmitted/
Founder (T/F) hiV strains reproduced 
Both the effect of MiF on the Production 
of Proinflammatory Mediators From hiV-
infected MDMs and also the enhanced 
Viral Production From Unactivated cD4+ 
T-cells stimulated With conditioned 
Media Derived From MiF-Treated  
hiV-infected MDMs
To examine whether the findings reported here could be 
exten ded to other HIV-1 strains, we generated viral stocks 
from selected transmitted/founder (T/F) IMCs. These clones 
were derived from full-length transmitted HIV-1 genomes and 
represent viruses actually responsible for productive clinical 
infection. Thus, these are instrumental tools for studying dif-
ferent aspects of HIV pathogenesis (36–39).
First, MDMs were infected with the R5 T/F virus. At day 
11, both infected and uninfected cells were treated with 0, 1, or 
25 ng/ml MIF and the production of cytokines was evaluated in 
cell supernatants. As observed for the HIV BAL strain, an MIF-
dependent effect was observed for IL-1β, IL-6, and IL-8, which 
was significantly marked in infected cells while the production 
of IL-10 was unaltered across conditions (Figure 8A). In par-
ticular, peak IL-6 and IL-8 effects were observed at 25  ng/ml 
MIF while for IL-1β, the effect was already evident at 1 ng/ml 
MIF. Contrary to our initial observations using the BAL strain, 
the production of TNF-α and sICAM was not affected by MIF 
(not shown).
Then, the effect of MDM supernatants on viral production 
from unactivated CD4+ T-cells was again tested but using the dual-
tropic T/F virus to infect the CD4+ T-cells. Thus, supernatants 
FigUre 7 | Identification of cytokines as responsible for enhancing human 
immunodeficiency virus type I (HIV-1) infection in unactivated CD4+ T-cells.  
(a) Unactivated CD4+ T-cells were stimulated with different combinations of 
cytokines for 72 h. Then, cells were infected and p24 antigen production was 
evaluated at days 4 and 7 post-infection. Each condition was compared with 
the corresponding RPMI condition (negative control). As a positive control, 
PHA stimulation was used. Percentage of living CD4+ T-cells (B) and 
percentage of infected (GFP+) CD4+ T-cells (c) after stimulation with the 
denoted treatments are shown. Data represent mean ± SD from four 
independent donors evaluated in duplicate. Concentrations of cytokines used 
in these experiments corresponded to the average concentrations found in 
monocyte-derived macrophage (MDM) supernatants stimulated with 25 ng/
ml macrophage migration inhibitory factor (MIF) (peak effect) as follows: 
250 pg/ml IL-6, 9,000 pg/ml IL-8, 1,400 pg/ml TNF-α, and 20 pg/ml IL-1β. 
(D) Neutralization of IL-8, IL-6, IL-1 β, and TNFα biological activity with 
monoclonal neutralizing antibodies. Primary CD4+ T-cells were incubated with 
supernatants derived from the 25 ng/ml MIF-treated HIV-infected MDM 
neutralized previously with 18 µg/ml anti-IL-8, 20 ng/ml anti-IL-6, 2 µg/ml 
anti-IL-1β, and 2 µg/ml anti-TNFα antibodies. Non-neutralized and isotype 
control antibody conditions were tested for comparison. Also, RPMI and PHA 
controls were included. Viral production was evaluated at day 4 post-
infection. Data were analyzed by one-way ANOVA followed by Dunnett’s 
post-test (all conditions versus the corresponding RMPI control) in (a) and 
Tukey’s post-test in (D). *p < 0.05.
FigUre 7 | Continued
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from MIF-treated BAL-infected and uninfected MDMs were 
used to stimulate unactivated CD4+ T-cells during 72  h. Viral 
production was evaluated at 4 and 7 days post-infection. Results 
indicated that production of a dual-tropic T/F virus from unac-
tivated CD4+ T-cells sensitized with supernatants derived from 
25 ng/ml MIF-treated infected MDMs was significantly higher 
compared to the uninfected counterpart (Figure 8B, right panel). 
Contrary, no effect was observed when using supernatants derived 
from 1 ng/ml MIF-treated MDMs (Figure 8B, left panel). These 
results partially recapitulated those obtained when infecting 
unactivated CD4+ T-cells with the X4-tropic NL4-3 laboratory 
strain: an enhancing effect on viral production was observed 
when sensitizing cells with MIF-treated infected MDM-derived 
supernatants although the kinetics seems to be different for the 
T/F strain.
Overall, MIF effect on the production of proinflammatory 
mediators from HIV-infected MDMs and also the enhancing 
effect of the conditioned media (derived from MIF-treated HIV-
infected MDMs) on viral production from unactivated CD4+ 
T-cells could be reproduced when using T/F viral strains. This 
provides further support to the notions presented in this work 
pointing toward a relevant role of the MIF/CD74 axis in HIV 
pathogenesis.
DiscUssiOn
It has become increasingly clear that signaling events down-
stream of MIF/CD74 interaction are key components in the 
regulation of immune responses that are involved in the patho-
genesis of different inflammatory and immune-mediated dis-
eases. However, whether this axis participates in HIV-mediated 
immune dysfunction has not been elucidated yet. Several 
lines of evidence suggest that this might be the case, based on 
the fact that CD74 expression is modulated in HIV-infected 
cells and that MIF plasma levels are elevated throughout the 
course of infection in HIV-infected subjects. Results depicted 
in this study provide support to this hypothesis by showing 
FigUre 8 | Infection of monocyte-derived macrophages (MDMs) and unactivated CD4+ T-cells with T/F viruses reproduce the results obtained with the R5-tropic 
(BAL) and the X4-tropic (NL4-3) laboratory strains. (a) Expression of IL-1β, IL-8, IL-6, and IL-10 in supernatants from uninfected (Un) and R5-tropic T/F-infected (In) 
MDMs. Data represent mean ± SD from three independent donors. Data were analyzed by two-way ANOVA followed by Tukey’s post-test. *p < 0.05, **p < 0.01, 
****p < 0.0001. (B) Human immunodeficiency virus (HIV) p24 antigen production from primary unactivated CD4+ T-cells incubated with supernatants from uninfected 
and infected MDMs treated with 1 ng/ml (left panel) or 25 ng/ml (right panel) macrophage migration inhibitory factor (MIF). Treated CD4+ T-cells were infected with a 
dual-tropic T/F virus and viral production was evaluated at 4 and 7 days post-infection. Data represent mean ± SD from five independent donors. Data were 
analyzed by two-way ANOVA followed by Sidak’s post-test. *p < 0.05.
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that production of soluble inflammatory factors by primary 
HIV-infected MDMs was increased in an MIF dose-dependent 
manner and that CD74/MIF interaction was necessary for 
this effect. Moreover, the conditioned environment generated 
by MIF/CD74 interaction in infected MDMs promotes CD4+ 
T-cell permissiveness to infection.
In an initial report, CD74 was described as the central com-
ponent of the MIF cell surface receptor (54). However, whereas the 
CD74 intracellular domain was shown to undergo intracellular 
phosphorylation upon engagement of the CD74 ectodomain by 
MIF, its short non-canonical structure suggested the involvement 
of a recruited co-receptor. A subsequent study demonstrated 
that CD44 was a necessary component for MIF signaling (16). 
CD74 surface expression has been shown to be upregulated in 
HIV-infected cells, and we show herein that this was also accom-
panied by surface CD44 upregulation which translated into an 
overlapping cell surface expression pattern observed specifically 
in WT HIV-infected cells. This allowed us to hypothesize that 
this phenomenon may translate into higher MIF receptor avail-
ability and enhanced receptor activation by MIF in these cells. 
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It is worth highlighting that only few reports describe the effect 
of HIV infection in CD44 expression in myeloid cells (55–57). 
Other molecules proposed to act as MIF coreceptors together 
with CD74, including CXCR2, CXCR4, and CXCR7 (17, 18, 58), 
were not analyzed here.
This evidence led us to study the MIF/CD74 interaction in 
HIV infection. First, we decided to study MIF-mediated modu-
lation of TLR4 in infected cells. This was based on the obser-
vation that detectable plasma LPS levels are common in HIV 
infection (2, 59), thus modulation of one of the components of 
LPS receptor complex, TLR4, might contribute to disease pro-
gression. Also, endogenous MIF has been shown to modulate 
TLR4 expression in murine macrophages (60, 61). Here, the 
effect of exogenously added MIF was studied to unravel how its 
interaction with CD74 might have an impact on TLR4 modula-
tion. In our system, a modest effect was observed particularly 
in infected cells at 25  ng/ml MIF with no evidence of CD74 
participation. A more recent report indicated that exogenously 
added MIF could modulate TLR4 in murine fibroblasts but 
only at 375  ng/ml MIF (15-fold higher concentration than 
in our system) (62). Regardless MIF stimuli, it is also worth 
pointing that TLR4 expression was lower in bystander cells, 
compared to the uninfected condition. We speculate that this 
might be the consequence of factors produced by productively 
infected cells that affect, directly or indirectly, the phenotype 
and/or function of the neighboring non-productively infected 
cells (63).
The capability of HIV-infected MDMs to secrete different 
proinflammatory cytokines in response to MIF treatment was 
examined later. The fact that MIF is able to stimulate the secretion 
of proinflammatory cytokines in different settings is a pheno-
menon well-documented (19, 64–66). Moreover, many of these 
events have been reported to occur after CD74 engagement and 
by activating multiple intracellular signaling pathways (7, 29, 
67–69). We add new evidence on the role of MIF in the clinically 
important HIV infection scenario. Quantitation of IL-1β, IL-6, 
IL-8, TNFα, and sICAM in MDMs supernatants demonstrated 
that MIF stimulation led to an augmented production of the 
proinflammatory cytokines studied. The first three cases showed 
a dose dependence with the MIF stimuli with maximum expres-
sion when using the highest MIF concentration tested. On the 
other hand, TNFα and sICAM production peaked at the lowest 
MIF concentration tested. Even more, enhanced production of 
IL-1β, IL-6, and IL-8 was also observed in MIF-treated MDMs 
infected with a T/F virus, indicating that this effect could be 
reproduced with clinically relevant viral strains. These results 
led to a direct link between the secretion of proinflammatory 
cytokines and MDM exposure to MIF. Even more relevant, the 
effect was maximum in infected cells compared to uninfected 
cells, pointing to a differential effect on HIV-infected cells. 
According to our hypothesis, this outcome could be explained 
by the higher availability of membrane CD74 molecules in 
HIV-infected cells that translate into greater MIF binding and 
signal transduction. To confirm that the MIF/CD74 axis was 
required for these effects, the interaction was blocked with a 
αCD74 immunoglobulin. The production of most mediators (all 
but sICAM) was inhibited by this treatment. In sum, our results 
provide support to the hypothesis that links the MIF/CD74 
interaction and the differential production of proinflammatory 
molecules such as IL-1β, IL-6, IL-8, and TNFα expression from 
HIV-infected cells. Of note, sICAM was proposed to promote 
interactions between B and T cells that ultimately render rest-
ing T-cells permissive to HIV infection (70). Thus, the finding 
regarding MIF-mediated induction of sICAM production was of 
special interest. Results indicated that sICAM response peaked 
at 1 ng/ml MIF and was then downmodulated at higher exog-
enous MIF concentrations. Again, this result might be reflecting 
the saturating action of autocrine/paracrine stimulation by 
endogenously produced MIF or the involvement of alternative 
mechanisms yet to be elucidated.
During the last years, the concept of macrophage polarization 
has gained special focus, thus distinguishing different MDM 
subsets with different functionalities (71). Here, unpolarized 
(i.e., differentiated from blood monocytes only in the presence 
of GM-CSF) MDMs were used throughout the study. This was 
based on bibliography indicating that M1 and M2 polarized 
MDMs are less efficient to support productive HIV infection 
compared to unpolarized cells due to different blocks imposed at 
different levels of the replicative cycle (72–74). On the other hand, 
it has been reported that MDM infection with HIV results in 
polarization toward an M1-like phenotype. Moreover, infection 
sensitized macrophage responses to TLR ligands (75). Despite 
TLR ligands were not assayed here, a parallelism between these 
and our findings can be proposed since, according to our results, 
HIV infection renders MDMs more reactive to a proinflamma-
tory stimuli such as MIF.
The hallmarks of HIV infection include the gradual decline 
in the number of CD4+ T-lymphocytes and the chronic 
and persistent inflammation and immune activation. HIV-
mediated immunopathogenesis is a complex process involv-
ing a dynamic interplay between viral and host molecules. 
Activation of T cells is driven directly by HIV replication but 
also by indirect mechanisms such as the breakdown in the gut 
mucosa and dysfunction of immunoregulatory factors, among 
others (2). Concomitantly, immune activation plays a key role 
in the systemic spread of the infection. HIV efficiently infects 
activated CD4+ T-cells leading to a productive infection state. 
However, it has been recently documented that the infection 
of unactivated CD4+ T-cells also occurs, resulting mostly in 
a latent infection (76). We therefore raised the question of 
whether MIF-treated MDM-derived supernatants could pro-
mote the infection of unactivated primary CD4+ T-cells in the 
absence of other stimuli. Results indicated that viral production 
was significantly enhanced by conditioned media obtained 
from MIF-treated HIV-infected MDMs (compared to MIF-
treated uninfected MDMs). The effect was highest as early as 
4 days post-infection when using the 25 ng/ml MIF-stimulated 
MDMs while it occurred at day 7 post-infection for the 1 ng/ml 
MIF condition. This pattern in viral production mirrors the 
MIF-dependent cytokine production from infected MDMs: 
a peak production of IL-1β, IL-6, and IL-8 was observed with 
25 ng/ml MIF and a peak in TNFα with 1 ng/ml. Particularly, 
TNFα showed the highest modulation magnitude when 
infected MDMs were compared with those uninfected but at 
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the lowest MIF concentration tested. In line with the depend-
ence on CD74/MIF interaction for MDM cytokine produc-
tion, blockade of MIF/CD74 engagement in infected MDMs 
abrogated the effect observed in CD4+ T  cells. In order to 
better support the impact of cytokines produced from infected 
MDMs downstream of the MIF/CD74 interaction on the per-
missiveness of unactivated CD4+ T-cells, recombinant cytokines 
were used as direct stimuli. When a combined treatment with 
IL-1β, IL-6, IL-8, and/or TNFα was attempted, viral production 
increased. In the same line, neutralizing the biological activity 
of these cytokines in MDM-derived supernatants resulted in 
diminished CD4+ T-cell permissiveness, resembling the same 
scenario obtained in the negative control. Finally, supernatants 
from MIF-treated HIV-infected MDMs could enhance viral 
production from unactivated CD4+ T-cells infected with a T/F 
virus suggesting that the proposed mechanism extends not 
only to laboratory strains but also to primary viral isolates.
The fact that cytokines enhance viral replication but, more 
importantly, promote the infection of resting CD4+ T-cells is 
not new (77). CCL19, CCL21, IL-7, and IL-15 are known to 
promote latent infection in resting CD4+ T-cells (78–80). Also, 
IL-6 and TNFα has been shown to facilitate infection of resting 
CD4+ T-cells and to induce productive infection (77, 81). In a 
particularly relevant report, soluble factors (sCD23 and sICAM) 
released by infected MDMs promoted the efficient infection 
of resting lymphocytes although the presence of B cells was a 
requisite for this effect (70). Nevertheless, it resulted interesting 
that the effect on resting CD4+ T-cell permissiveness mediated 
by sCD23 and sICAM, occurred without promoting cell activa-
tion and proliferation, which is in line with the observations 
described in this work. In a recent report, Morris et  al. (81) 
described that IL-6 produced from endothelial cells increased 
productive HIV infection in resting CD4+ T-cells. Even more, 
this effect was not accompanied by an increase in the expres-
sion of T  cell activation markers, mirroring our own results. 
Although the mechanism underlying this phenomenon was not 
studied by the authors, it could be associated with the capacity of 
IL-6 to favor CD4+ T-cell cycling and survival (82). On the other 
hand, IL-8 and TNFα have been reported to directly enhance 
the rate of productive infection in activated T  cells (82, 83). 
In particular, binding of TNFα to its receptor triggers several 
signaling cascades, including NF-κB, MAPK, ERK, and JNK 
pathways, which directly enhances transcription from the LTR 
promoter both on models of productive HIV infection and also 
in latently infected cells [reviewed in Ref. (82)].
Thus, in our model we suggest that IL-6, IL-8, TNFα, and IL-1β 
might be acting synergistically at different levels (i.e., modifying 
the cellular environment and/or by enhancing transcriptional 
and/or post-transcriptional mechanisms) to promote, at least 
transiently, the productive infection of unactivated CD4+ T cells. 
This could explain that no effect was observed when cells were 
treated with a single or a dual combination of the cytokines 
studied. It will be a matter of subsequent studies to investigate if 
this also results in a higher rate of latent infection in these cells. 
Finally, the role of IL-1β is less clear since there is no definite 
report suggesting a direct mechanism of IL-1β-mediated modu-
lation of HIV replication in T-cells.
Taken together, we postulate that modulation of CD74 by 
HIV infection in MDMs leads to the enhanced susceptibility of 
these cells to MIF stimulation, which may have an impact on the 
spread of HIV infection and the enhancement of viral-mediated 
pathogenesis. The current results indicate that the expres sion 
of proinflammatory cytokines was significantly higher in MIF- 
stimulated infected MDMs compared to MIF-stimulated unin-
fected MDMs. In addition, this proinflammatory microenviron-
ment, conditioned positively primary unactivated CD4+ T cells 
to HIV-1 infection. The methodological strengths of this work 
include the exclusive use of primary cells, emphasizing that treat-
ment effects can be observed despite interdonor variability, the use 
of both laboratory and T/F viral strains, and the employment of 
physiological MIF concentrations as stimuli. On the other hand, 
interdonor variability and the use of a limited number of donors 
might have masked differences across conditions, representing 
an important limitation of the study. Also, macrophages exhibit 
significant heterogeneity in vivo, as already discussed and this fact 
should not be overlooked. Thus, results might not be extended to 
polarized MDMs, tissue macrophages, or other HIV susceptible 
myeloid cells such as dendritic cells. For instance, it would be 
very interesting to evaluate CD74/MIF axis in microglial cells. If a 
similar hypothesis was confirmed in this model, this mechanism 
could be associated with the development of HIV-related neuro-
logical complications.
Overall, this work provides further insights in the role of mac-
rophages in HIV infection, not only as a cell type which supports 
viral replication itself but also as a source of soluble factors that 
facilitate viral dissemination. Evidence gathered here suggests 
that CD74/MIF interaction could be implicated in modulating 
viral reservoir seeding, persistent viremia and inflammation—all 
key aspects of HIV immunophatogenesis. Data presented here 
support further studies to fully understand how this mechanism 
operates in HIV infection and to explore the possibility to target 
CD74/MIF axis as a therapy aimed at reducing inflammation and 
reservoir size during HIV infection.
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(MDMs) or versus GFP plot (CD4+ T-cells). Data acquisition was performed in a 
BD FACSCanto flow cytometer using the BD FACSDiva software and analyzed 
subsequently with FlowJO v10 software (Data Analysis Software, LLC).
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